EBMT 2023 | UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Trust, Bristol, UK, describes some of the key findings of the UKALL14 trial (NCT01085617). Prof. Marks explains that applying four doses of rituximab with standard chemotherapy did not significantly improve outcomes in B-cell acute lymphoblastic leukemia (B-ALL). In addition, the trial showed that reduced-intensity allogeneic stem cell transplantation (alloSCT) led to better outcomes than chemotherapy, and that MRD-positivity prior to transplant affected outcomes negatively. The trial also evaluated the impact of nelarabine consolidation in T-ALL. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Kite
